MADRIGAL PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.26B
↑+20.9% +$217Mvs FY2024
Total Liabilities
$657M
↑+128.2% +$369Mvs FY2024
Equity
$603M
↓-20.1% -$152Mvs FY2024
Cash
$199M
↑+98.7% +$99Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.26B | $1.04B |
| Current Assets | $1.25B | $1.03B |
| Cash | $199M | $100M |
| ST Investments | $0 | $0 |
| Receivables | $134M | $54M |
| Inventory | $75M | $34M |
| Other Current | $838M | $845M |
| Non-Current Assets | $14M | $9M |
| PPE | $1M | $2M |
| Goodwill | $0 | $0 |
| Intangibles | $7M | $5M |
| Investments | $0 | $0 |
| Other Non-Current | $5M | $2M |
| Total Liab+Eq | $1.26B | $1.04B |
| Current Liab. | $310M | $169M |
| Accounts Payable | $49M | $44M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $261M | $126M |
| Non-Current Liab. | $347M | $119M |
| Long-Term Debt | $340M | $118M |
| Other LT Liab. | $7M | $1M |
| Equity | $603M | $754M |
| Retained Earnings | $2.09B | $1.80B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · MDGL · Comparing FY2025 vs FY2024